Showing results (151-160 of 231) with videos related to

Sort By:
Pageof 24
Rheumatology (Oxford, England)|June 10, 2022
The BILAG-2004 index is associated with development of new damage in SLEChee-Seng Yee, Caroline Gordon, Mohammed Akil, et al.
Annals of the Rheumatic Diseases|February 14, 2012
Comprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohortJohn Bowes, Pauline Ho, Edward Flynn, et al.
Arthritis and Rheumatism|September 30, 2006
Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activityChee-Seng Yee, Vernon Farewell, David A Isenberg, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2016
Tartrate-Resistant Acid Phosphatase Deficiency in the Predisposition to Systemic Lupus ErythematosusJie An, Tracy A Briggs, Audrey Dumax-Vorzet, et al.
Rheumatology (Oxford, England)|December 8, 2020
BSR guideline on the management of adults with systemic lupus erythematosus (SLE) 2018: baseline multi-centre audit in the UKFiona A Pearce, Megan Rutter, Ravinder Sandhu, et al.
Annals of the Rheumatic Diseases|February 26, 2011
Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgarisJohn Bowes, Steve Eyre, Edward Flynn, et al.
The Journal of Rheumatology|December 4, 2009
Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) studySahena Haque, Caroline Gordon, David Isenberg, et al.
Nature Genetics|November 6, 2007
Rheumatoid arthritis association at 6q23Wendy Thomson, Anne Barton, Xiayi Ke, et al.
Lancet (London, England)|July 26, 2018
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trialDaniel J Wallace, Richard A Furie, Yoshiya Tanaka, et al.
Pageof 24